54 related articles for article (PubMed ID: 23203543)
21. Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.
Matsuyama N; Tsutsumi T; Kubota N; Nakajima T; Suzuki H; Takeyama Y
Hypertens Res; 2009 Aug; 32(8):721-6. PubMed ID: 19590505
[TBL] [Abstract][Full Text] [Related]
22. Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats.
Takemori K; Ishida H; Ito H
Life Sci; 2005 Sep; 77(18):2233-45. PubMed ID: 15963533
[TBL] [Abstract][Full Text] [Related]
23. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists.
Bao X; Zhu W; Yuan W; Zhu X; Yan Y; Tang H; Chen Z
Eur J Med Chem; 2016 Nov; 123():115-127. PubMed ID: 27474928
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
Olins GM; Corpus VM; Chen ST; McMahon EG; Palomo MA; McGraw DE; Smits GJ; Null CL; Brown MA; Bittner SE
J Cardiovasc Pharmacol; 1993 Oct; 22(4):617-25. PubMed ID: 7505365
[TBL] [Abstract][Full Text] [Related]
27. N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation.
Zhu W; Bao X; Ren H; Da Y; Wu D; Li F; Yan Y; Wang L; Chen Z
Eur J Med Chem; 2016 Jun; 115():161-78. PubMed ID: 27017546
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats.
Zhou J; Ando H; Macova M; Dou J; Saavedra JM
J Cereb Blood Flow Metab; 2005 Jul; 25(7):878-86. PubMed ID: 15729290
[TBL] [Abstract][Full Text] [Related]
29. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system.
Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs.
Bao X; Zhu W; Zhang R; Wen C; Wang L; Yan Y; Tang H; Chen Z
Bioorg Med Chem; 2016 May; 24(9):2023-31. PubMed ID: 27004954
[TBL] [Abstract][Full Text] [Related]
32. Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals.
Wu MY; Ma XJ; Yang C; Tao X; Liu AJ; Su DF; Liu JG
Acta Pharmacol Sin; 2009 Mar; 30(3):307-13. PubMed ID: 19262554
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs.
Nakao S; Mabuchi M; Shimizu T; Itoh Y; Takeuchi Y; Ueda M; Mizuno H; Shigi N; Ohshio I; Jinguji K; Ueda Y; Yamamoto M; Furukawa T; Aoki S; Tsujikawa K; Tanaka A
Bioorg Med Chem Lett; 2014 Feb; 24(4):1071-4. PubMed ID: 24461353
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives.
Dhingra N; Bhardwaj TR; Mehta N; Mukhopadhyay T; Kumar A; Kumar M
Arch Pharm Res; 2011 Jul; 34(7):1055-63. PubMed ID: 21811911
[TBL] [Abstract][Full Text] [Related]
35. Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3β.
Thomas E; Thankan RS; Purushottamachar P; Guo J; Parise RA; Beumer JH; Njar VCO
Steroids; 2023 Apr; 192():109184. PubMed ID: 36702363
[TBL] [Abstract][Full Text] [Related]
36. A New Anti-hypertensive Drug-Guanethidin.
Can Med Assoc J; 1960 Jun; 82(24):1238-9. PubMed ID: 20326320
[No Abstract] [Full Text] [Related]
37. New Anti-Periodics.
Med Exam (Phila); 1853 Nov; 9(107):719-720. PubMed ID: 38121742
[No Abstract] [Full Text] [Related]
38. Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.
Da YJ; Yuan WD; Zhu LF; Chen ZL
Arzneimittelforschung; 2012 Dec; 62(12):637-43. PubMed ID: 23203543
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Da YJ; Yuan WD; Xin T; Nie YY; Ye Y; Yan YJ; Liang LS; Chen ZL
Bioorg Med Chem; 2012 Dec; 20(24):7101-11. PubMed ID: 23122933
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of a new angiotensin II receptor antagonist.
Zheng HL; Zhu WB; Wu D; Da YJ; Yan YJ; Bian J; Chen ZL
Drug Res (Stuttg); 2014 Dec; 64(12):656-62. PubMed ID: 24573978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
